Diabetes Core Update Special Edition: SGLT-2 inhibitors – Renal Effects– December 2020

In this second episode of a three-part series on SGLT-2 inhibitors Drs. John Russell and Neil Skolnik discuss the renal effects of the SGLT-2 inhibitors, as well as the place of the SGLT-2is in the American Diabetes Association Guidelines and address practical issues about SGLT-2 inhibitor use.  In episode 1, Drs. Russell and Skolnik discussed an overview of the CVOTs for the SGLT-2 inhibitors and in episode 3 they will focus heart failure outcomes.  This special three-part series is supported by independent educational grant from AstraZeneca.

For more information about each of ADA’s science and medical journals, please visit www.diabetesjournals.org.

Presented by:

Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health

John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Director, Family Medicine Residency Program, Chair-Department of Family Medicine, Abington Jefferson Health